Drug
Enclomiphene clinical trials
Also written Androxal.
- studies test it
- 25
- open now
- 0
- in phase 3
- 10
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2014 (8)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 8 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 7
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 1
Repros Therapeutics Inc. (24) · Baylor College of Medicine (1)
Studies
Open first, then newest update. How each study uses Enclomiphene is read from its arms, and is right about nine times in ten.
Testing it · 25
- Androxal in Male InfertilityWithdrawnPhase 2/3Baylor College of MedicineNCT02160704Written as Enclomiphene citrate
- A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg EnclomipheneCompletedPhase 2Repros Therapeutics Inc.NCT02651688Written as Enclomiphene
- Comparison of Two Formulations of AndroxalCompletedPhase 1Repros Therapeutics Inc.NCT01984398Written as 12.5 mg Androxal Formulation A
- The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)CompletedPhase 2Repros Therapeutics Inc.NCT01386606Written as Androxal (enclomiphene citrate)
- To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical TestosteroneCompletedPhase 2Repros Therapeutics Inc.NCT00706719Written as 25 mg Androxal
- Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary HypogonadismCompletedPhase 3Repros Therapeutics Inc.NCT01739595Written as enclomiphene citrate
- Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary HypogonadismCompletedPhase 3Repros Therapeutics Inc.NCT01532414Written as Androxal
- An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral AdministrationCompletedPhase 1Repros Therapeutics Inc.NCT02274181Written as Androxal
- A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%CompletedPhase 3Repros Therapeutics Inc.NCT01993225Written as Androxal 12.5 mg/25 mg
- A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%CompletedPhase 3Repros Therapeutics Inc.NCT01993212Written as Androxal 12.5 mg or 25 mg
- An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of AndroxalCompletedPhase 1Repros Therapeutics Inc.NCT02169804Written as Androxal 25 mg
- Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary HypogonadismCompletedPhase 3Repros Therapeutics Inc.NCT01619683Written as enclomiphene citrate
- Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy MalesCompletedPhase 1Repros Therapeutics Inc.NCT01991327Written as Androxal
- Study to Evaluate the Effect of Food Upon the Pharmacokinetics of AndroxalCompletedPhase 1Repros Therapeutics Inc.NCT02146391Written as Androxal 25 mg Capsules
- Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal FunctionCompletedPhase 1Repros Therapeutics Inc.NCT01923857Written as Androxal 25 mg
- A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of AndroxalCompletedPhase 1Repros Therapeutics Inc.NCT01959685Written as Androxal
- Normalization of Morning Testosterone Levels in Men With Secondary HypogonadismCompletedPhase 2Repros Therapeutics Inc.NCT01270841Written as Androxal
- Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes MellitusCompletedPhase 2Repros Therapeutics Inc.NCT01191320Written as Androxal
- Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary HypogonadismCompletedPhase 3Repros Therapeutics Inc.NCT01534208Written as Androxal
- Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary HypogonadismCompletedPhase 3Repros Therapeutics Inc.NCT01067365Written as Androxal
Codes
What other systems call Enclomiphene · ClinicalTrials.gg INT008968
- MeSH (NLM) D064695EnclomipheneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) R6D2UI4FLSENCLOMIPHENEConfirmed FDA, NLM
- NCI Thesaurus C28211EnclomipheneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D064695 | Enclomiphene | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | R6D2UI4FLS | ENCLOMIPHENE | Confirmed FDA, NLM |
| NCI Thesaurus | C28211 | Enclomiphene | One source FDA |
Also registered as enclomiphene citrate (UNII J303A6U9Y6).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.